The Federal Bureau of Medicine plans to begin a review of several hundred drugs in 13 categories with respect to their efficacy under the Kefauver-Harris Amendments to the Federal Food, Drug, and Cosmetic Act.
Joseph F. Sadusk Jr., MD, medical director of the Food and Drug Administration, said the categories, first announced in May, 1964, will be reviewed according to the following priority:
Proteolytic enzymes (oral and injectable).
Drugs offered for apprehensive and anxiety states, most tranquilizers, monoamine oxidase inhibitors.
Nonprescription iron preparations.
Topical ophthalmic antibiotic combinations.
A number of sustained-release drugs.
Other topical antibiotic combination products.
Drugs used in pregnancy.
Topical 'caines (local anesthetics).
"It must be realized," Sadusk said, "that this order of priority may change with time and indeed certain specific drugs, or even categories